Literature DB >> 9437435

The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy.

M C Cavallo1, G Fattore.   

Abstract

The purpose of this study was to measure resource consumption associated with the provision of nonmedical care to noninstitutionalized patients with Alzheimer disease (AD) residing in the Lombardy Region of Italy. A questionnaire was mailed to 1,501 caregivers who sought advice from the "Federation Alzheimer Italia" in 1995. On the basis of 616 returned questionnaires, the authors estimated that a patient with AD requires 18 hours per week of paid nonmedical services and 45 hours per week of personal care provided by a primary caregiver. Primary caregivers are more likely to be women, spouses, and retired. Almost 7 of 10 patients are supported by at least a second caregiver. Annual expenditure for nonmedical cost per patient with AD is estimated to be L 13,388,000 (U.S. $8,218). Using the replacement cost approach, the authors estimated the economic cost of informal (unpaid) care to be L 72,877,000 (U.S. $44,736). Despite some limitations in the design of the survey, this first Italian study on primary data highlights the impressive economic burden of AD on families. It also shows that AD puts many Italian families at great financial risk. Adequate and timely funding arrangements should be urgently found to make resources available to future generations of patients.

Entities:  

Mesh:

Year:  1997        PMID: 9437435

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  15 in total

Review 1.  The epidemic of Alzheimer's disease. How can we manage the costs?

Authors:  N Johnson; T Davis; N Bosanquet
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

2.  Health economics and health policy issues in Alzheimer's disease.

Authors:  T Rapp
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

3.  Formal and Informal Care of Community-Living Older People: A Population-Based Study from the Swedish National Study on Aging and Care.

Authors:  A Wimo; S Elmståhl; L Fratiglioni; B-M Sjölund; A Sköldunger; C Fagerström; J Berglund; M Lagergren
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

Review 4.  Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Economic valuation and determinants of informal care to people with Alzheimer's disease.

Authors:  Luz María Peña-Longobardo; Juan Oliva-Moreno
Journal:  Eur J Health Econ       Date:  2014-05-07

Review 6.  The cost of dementia in Europe: a review of the evidence, and methodological considerations.

Authors:  Linus Jönsson; Anders Wimo
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Methodological considerations in cost of illness studies on Alzheimer disease.

Authors:  Nagede Costa; Helene Derumeaux; Thomas Rapp; Valérie Garnault; Laura Ferlicoq; Sophie Gillette; Sandrine Andrieu; Bruno Vellas; Michel Lamure; Alain Grand; Laurent Molinier
Journal:  Health Econ Rev       Date:  2012-09-11

Review 8.  Comparison of informal care time and costs in different age-related dementias: a review.

Authors:  Nadège Costa; Laura Ferlicoq; Hélène Derumeaux-Burel; Thomas Rapp; Valérie Garnault; Sophie Gillette-Guyonnet; Sandrine Andrieu; Bruno Vellas; Michel Lamure; Alain Grand; Laurent Molinier
Journal:  Biomed Res Int       Date:  2012-12-05       Impact factor: 3.411

9.  Long-term care eligibility criteria for people with Alzheimer's disease.

Authors:  P Fox; K Maslow; X Zhang
Journal:  Health Care Financ Rev       Date:  1999

Review 10.  The economic cost of Alzheimer's disease: Family or public health burden?

Authors:  Diego M Castro; Carol Dillon; Gerardo Machnicki; Ricardo F Allegri
Journal:  Dement Neuropsychol       Date:  2010 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.